MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

SOX9

  • Home
  • SOX9
Targeting SOX9-Driven SPEM Plasticity: A New Therapeutic Avenue to Prevent Gastric Cancer Progression
Posted inGastroenterology news Oncology

Targeting SOX9-Driven SPEM Plasticity: A New Therapeutic Avenue to Prevent Gastric Cancer Progression

Posted by By MedXY 07/16/2026
SOX9 is a pivotal regulator of SPEM cell plasticity driving gastric metaplasia and carcinogenesis. Therapeutically targeting SOX9 may prevent the progression of pre-cancerous lesions to gastric cancer by blocking metaplastic evolution.
Read More
Therapeutic Reversal of SOX9-Mediated Chemoresistance in Esophageal Adenocarcinoma via APE1-Redox Inhibition
Posted inClinical Updates news Oncology

Therapeutic Reversal of SOX9-Mediated Chemoresistance in Esophageal Adenocarcinoma via APE1-Redox Inhibition

Posted by By MedXY 03/15/2026
This review details a breakthrough in esophageal adenocarcinoma treatment, identifying the APE1-SOX9 axis as a primary driver of chemoresistance and demonstrating how targeting APE1's redox function can sensitize tumors to oxaliplatin.
Read More
  • Noncombustible Nicotine or Tobacco Product Use After Smoking Cessation and Major Vision-Impairing Diseases: Evidence from a Nationwide Cohort Study and Clinical Implications
  • Advancing Inner Ear Imaging: A Synchrotron-Based Deep Learning Network Outperforms Expert Segmentation in Clinical CT Scans
  • KRAS Mutations in Duodenal Lavage Fluid After Secretin Stimulation: A Novel Biomarker for Early Detection of Pancreatic Cancer
  • Ensuring Lasting Impact: Strategies for Sustainable Implementation of Surgical Trials in Gynecologic Oncology
  • Determinants and Outcomes of Vessel Recanalization Following Acute Cervical Artery Dissection: Insights from an International Multicenter Cohort
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation ischemic stroke MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top